BRPI0816852A2 - método de diagnosticar ou prognosticar doença ou desordem em sujeito, biomarcador, método para determinar e/ou prever se sujeito tem diferenciação da desordem, biomarcador para desordem pulmonar, método para diagnosticar se sujeito tem, ou está em risco de desenvolver doença ou desordem, método de inibir a proliferação de doença ou desordem e método para identificar agente terapêutico do câncer. - Google Patents

método de diagnosticar ou prognosticar doença ou desordem em sujeito, biomarcador, método para determinar e/ou prever se sujeito tem diferenciação da desordem, biomarcador para desordem pulmonar, método para diagnosticar se sujeito tem, ou está em risco de desenvolver doença ou desordem, método de inibir a proliferação de doença ou desordem e método para identificar agente terapêutico do câncer.

Info

Publication number
BRPI0816852A2
BRPI0816852A2 BRPI0816852A BRPI0816852A BRPI0816852A2 BR PI0816852 A2 BRPI0816852 A2 BR PI0816852A2 BR PI0816852 A BRPI0816852 A BR PI0816852A BR PI0816852 A BRPI0816852 A BR PI0816852A BR PI0816852 A2 BRPI0816852 A2 BR PI0816852A2
Authority
BR
Brazil
Prior art keywords
disorder
subject
disease
biomarker
diagnosing
Prior art date
Application number
BRPI0816852A
Other languages
English (en)
Inventor
B Marsh Clay
G Piper Melissa
Ismail Noura
Original Assignee
Univ Ohio State Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Ohio State Res Found filed Critical Univ Ohio State Res Found
Publication of BRPI0816852A2 publication Critical patent/BRPI0816852A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6809—Methods for determination or identification of nucleic acids involving differential detection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/10—Applications; Uses in screening processes
    • C12N2320/12—Applications; Uses in screening processes in functional genomics, i.e. for the determination of gene function
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/16—Primer sets for multiplex assays
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Plant Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
BRPI0816852A 2007-09-14 2008-09-12 método de diagnosticar ou prognosticar doença ou desordem em sujeito, biomarcador, método para determinar e/ou prever se sujeito tem diferenciação da desordem, biomarcador para desordem pulmonar, método para diagnosticar se sujeito tem, ou está em risco de desenvolver doença ou desordem, método de inibir a proliferação de doença ou desordem e método para identificar agente terapêutico do câncer. BRPI0816852A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99380907P 2007-09-14 2007-09-14
US5517808P 2008-05-22 2008-05-22
PCT/US2008/076109 WO2009036236A1 (en) 2007-09-14 2008-09-12 Mirna expression in human peripheral blood microvesicles and uses thereof

Publications (1)

Publication Number Publication Date
BRPI0816852A2 true BRPI0816852A2 (pt) 2017-06-06

Family

ID=40452488

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0816852A BRPI0816852A2 (pt) 2007-09-14 2008-09-12 método de diagnosticar ou prognosticar doença ou desordem em sujeito, biomarcador, método para determinar e/ou prever se sujeito tem diferenciação da desordem, biomarcador para desordem pulmonar, método para diagnosticar se sujeito tem, ou está em risco de desenvolver doença ou desordem, método de inibir a proliferação de doença ou desordem e método para identificar agente terapêutico do câncer.

Country Status (10)

Country Link
US (3) US8455199B2 (pt)
EP (3) EP2190992B1 (pt)
JP (1) JP5624470B2 (pt)
CN (2) CN101842484B (pt)
AU (1) AU2008298744B8 (pt)
BR (1) BRPI0816852A2 (pt)
CA (1) CA2699646A1 (pt)
ES (2) ES2575868T3 (pt)
IL (2) IL204484A (pt)
WO (1) WO2009036236A1 (pt)

Families Citing this family (145)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2461189T3 (es) 2006-01-05 2014-05-19 The Ohio State University Research Foundation Métodos basados en microARN y composiciones para el diagnóstico y el tratamiento de cánceres sólidos de mama o pulmón
EP2369012A1 (en) 2006-03-20 2011-09-28 The Ohio State University Research Foundation Micro-RNA fingerprints during human megakaryocytopoiesis
IL282783B2 (en) 2006-05-18 2023-09-01 Caris Mpi Inc A system and method for determining a personalized medical intervention for a disease stage
US8768629B2 (en) 2009-02-11 2014-07-01 Caris Mpi, Inc. Molecular profiling of tumors
EP2117305A4 (en) 2007-01-26 2011-03-30 Univ Louisville Res Found MODIFICATION OF EXOXIC COMPONENTS USED AS VACCINE
CN101918424A (zh) * 2007-06-15 2010-12-15 俄亥俄州立大学研究基金会 用于靶向由Drosha介导的微小RNA加工的致癌ALL-1融合蛋白
EP2806273B1 (en) 2007-07-25 2017-09-06 University of Louisville Research Foundation, Inc. Exosome-associated microRNA as a diagnostic marker
ES2627059T3 (es) 2007-08-03 2017-07-26 The Ohio State University Research Foundation Regiones ultraconservadas que codifican ARNnc
US20100255514A1 (en) 2007-08-16 2010-10-07 The Royal Institution For The Advancement Of Learning/Mcgill University Tumor cell-derived microvesicles
CA2733672C (en) 2007-08-16 2018-09-11 The Royal Institution For The Advancement Of Learning/Mcgill University Tumor cell-derived microvesicles
ES2575868T3 (es) 2007-09-14 2016-07-01 The Ohio State University Research Foundation Expresión de miARN en microvesículas de sangre periférica humana y sus usos
CN101424640B (zh) * 2007-11-02 2012-07-25 江苏命码生物科技有限公司 血清中微小核糖核酸的检测方法和用于检测的试剂盒、生物芯片及其制作和应用方法
US20110053157A1 (en) * 2008-02-01 2011-03-03 The General Hospital Corporation Use of microvesicles in diagnosis, prognosis and treatment of medical diseases and conditions
WO2010018564A1 (en) * 2008-08-13 2010-02-18 Rosetta Genomics Ltd. Compositions and methods for determining the prognosis of bladder urothelial cancer
CA2742324A1 (en) 2008-10-30 2010-06-03 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Methods for assessing rna patterns
EP2350320A4 (en) 2008-11-12 2012-11-14 Caris Life Sciences Luxembourg Holdings METHODS AND SYSTEMS FOR USING EXOSOMES TO DETERMINE PHENOTYPES
US20130178383A1 (en) * 2008-11-12 2013-07-11 David Spetzler Vesicle isolation methods
DK2425016T3 (en) * 2009-04-29 2015-06-29 Amc Amsterdam MEANS AND METHODS TO REMEDY THE, PREVENT AND / OR diagnose heart failure or EN risk of cardiac failure
EP2336353A1 (en) * 2009-12-17 2011-06-22 febit holding GmbH miRNA fingerprints in the diagnosis of diseases
KR20120037992A (ko) * 2009-07-16 2012-04-20 더 제너럴 하스피탈 코포레이션 핵산 분석
WO2011031877A1 (en) 2009-09-09 2011-03-17 The General Hospital Corporation Use of microvesicles in analyzing nucleic acid profiles
US20130029339A1 (en) 2009-09-09 2013-01-31 The General Hospital Corporation Use of microvesicles in analyzing kras mutations
US20120231970A1 (en) * 2009-09-30 2012-09-13 Japan Health Sciences Foundation Colon cancer marker and method for testing for colon cancer
WO2011039757A2 (en) * 2009-10-04 2011-04-07 Rosetta Genomics Ltd. Compositions and methods for prognosis of renal cancer
US8648017B2 (en) 2009-11-04 2014-02-11 Diamir, Llc Methods of using small RNA from bodily fluids for diagnosis and monitoring of neurodegenerative diseases
EP2504452A4 (en) 2009-11-23 2014-06-11 Univ Ohio State Res Found SUBSTANCES AND METHODS THAT CAN BE USED TO ACT ON THE GROWTH, MIGRATION, AND INVASION OF TUMOR CELLS
EP2327783A1 (en) * 2009-11-27 2011-06-01 Universitätsklinikum Freiburg Pharmaceutical composition comprising miRNA-100 and its use in the modulation of blood vessel growth
CN102080086B (zh) * 2009-12-01 2012-12-26 中国科学院上海药物研究所 人miR-133a反义核酸及其应用
CN102080083B (zh) * 2009-12-01 2013-02-27 中国科学院上海药物研究所 人miR-149反义核酸及其应用
US20120302626A1 (en) * 2009-12-04 2012-11-29 Sandeep Dave Microrna and use thereof in identification of b cell malignancies
WO2011076141A1 (en) * 2009-12-24 2011-06-30 Fudan University Diagnostic kits comprising microrna biomarkers and methods for diagnosis of hepatocellular cancer
CN102892897B (zh) * 2009-12-24 2016-08-03 复旦大学 用于肺癌的微rna表达谱分析的组合物和方法
CN102892898B (zh) * 2009-12-24 2016-03-09 复旦大学 用于肝细胞癌诊断的含微rna生物标记的诊断试剂盒和方法
CN102770560B (zh) * 2009-12-24 2015-11-25 复旦大学 用于早期检测结直肠癌的基于血浆的微rna生物标记及方法
WO2011076147A1 (en) * 2009-12-24 2011-06-30 Fudan University Plasma-based micro-rna biomarkers and methods for early detection of colorectal cancer
EP2341145A1 (en) * 2009-12-30 2011-07-06 febit holding GmbH miRNA fingerprint in the diagnosis of diseases
EP2354246A1 (en) 2010-02-05 2011-08-10 febit holding GmbH miRNA in the diagnosis of ovarian cancer
CA2791905A1 (en) * 2010-03-01 2011-09-09 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarkers for theranostics
EP2363136A1 (en) * 2010-03-02 2011-09-07 Fresenius Medical Care Deutschland GmbH Microvesicles (MVs) derived from adult stem cells for use in the therapeutic treatment of a tumor disease
JP2011211955A (ja) * 2010-03-31 2011-10-27 Toray Ind Inc 肝ガン患者予後予測用組成物及び方法
JP2013526852A (ja) * 2010-04-06 2013-06-27 カリス ライフ サイエンシズ ルクセンブルク ホールディングス 疾患に対する循環バイオマーカー
EP2559442B1 (en) * 2010-04-13 2017-12-06 Jiangsu Mingma Biotech Co., Ltd Method for regulating microrna content in organisms and uses thereof
WO2011140182A2 (en) * 2010-05-04 2011-11-10 Medimmune, Llc Optimized degenerative muscle disease diagnostics and treatments
EP2576785A4 (en) 2010-06-04 2014-12-24 Univ Texas REGULATION OF METABOLISM BY MIR-378
US20110318742A1 (en) * 2010-06-23 2011-12-29 The Chinese University Of Hong Kong Micro rna markers for colorectal cancer
CA2802738A1 (en) * 2010-06-24 2011-12-29 The Ohio State University Chronic lymphocytic leukemia modeled in mouse by targeted mir-29 expression
WO2012031008A2 (en) 2010-08-31 2012-03-08 The General Hospital Corporation Cancer-related biological materials in microvesicles
CN103221542A (zh) * 2010-09-27 2013-07-24 萨班哲大学 miRNA用于诊断、预防、治疗和追踪涉及巨自噬异常的疾病的用途
US20130295574A1 (en) 2010-11-10 2013-11-07 Exosome Diagnostics, Inc. Method for Isolation of Nucleic Acid Containing Particles and Extraction of Nucleic Acids Therefrom
WO2012063894A1 (ja) * 2010-11-12 2012-05-18 国立大学法人愛媛大学 マイクロｒｎａのアンチセンスオリゴヌクレオチドを含む組成物
AU2011326032B2 (en) 2010-11-12 2016-10-06 The Ohio State University Research Foundation Materials and methods related to microRNA-21, mismatch repair, and colorectal cancer
BR112013011942A2 (pt) 2010-11-15 2016-11-01 Univ Michigan formulação, forma de dosagem de droga para administração transmucosa oral, sistema transmucoso de fornecimento de droga, método de tratamento e profilaxia de uma doença ou distúrbio, método de tratamento, formulação, método para tratamento ou prevenção de carcinoma de célula escamosa de cabeça e pescoço (hnscc), método para quimioprevenção de um câncer oral ou condição pré-cancerosa, método para aumentar a concentração de uma composição de retinida, método de tratamento e profilaxia de uma doença ou condição, método de ratamento de um sujeito apresentando uma condição médica sintomática, método de tratamento de um câncer oral ou condição pré-cancerosa num paciente, método para fazer um sistema de fornecimento de droga bucal, método para aumentar a liberação e permeação de uma composição de retinida.
BR112013012319A2 (pt) 2010-12-15 2019-09-24 Miragen Therapeutics inibidores de micro rna compreendendo nucleotídeos bloqueados
CN102140465B (zh) * 2010-12-30 2013-06-12 苏州吉玛基因股份有限公司 人miR-1249反义核酸及其应用
CN102146412B (zh) * 2011-01-11 2012-10-03 中山大学 一种小分子非编码RNA 基因hsa-miR-29b 及其应用
US9045749B2 (en) 2011-01-14 2015-06-02 The General Hospital Corporation Methods targeting miR-128 for regulating cholesterol/lipid metabolism
RU2626540C2 (ru) * 2011-04-18 2017-07-28 Диамир, Ллс Способы обнаружения патологических изменений в органе или системе органов
EP2596136B1 (en) * 2011-05-06 2014-07-16 Zhongshan Hospital Fudan University Marker consisting of plasma microrna and new method for diagnosis of hepatocellular carcinoma
WO2013003350A2 (en) * 2011-06-27 2013-01-03 Eisai R&D Management Co., Ltd. Microrna biomarkers indicative of alzheimer's disease
CN102250904B (zh) * 2011-07-13 2013-11-13 中国科学技术大学 一种预防和/或治疗黑色素瘤的药物
US20150018227A1 (en) * 2011-08-05 2015-01-15 University Of Louisville Research Foundation, Inc. Microrna biomarkers
US20150024389A1 (en) * 2011-09-16 2015-01-22 Lsip, Llc Method for detecting bladder cancer cells, primer used in method for detecting bladder cancer cells, and bladder cancer marker
CN102433339B (zh) * 2011-09-16 2012-10-03 山东莱博生物科技有限公司 一种HCV核酸适配体及其在制备HCV-cAg检测试剂盒中的应用
EP2763703B1 (en) 2011-10-06 2018-02-14 Miragen Therapeutics, Inc. Control of whole body energy homeostasis by microrna regulation
JP2014530612A (ja) 2011-10-14 2014-11-20 ジ・オハイオ・ステート・ユニバーシティ 卵巣がんに関する方法および材料
EP2584040A1 (en) * 2011-10-17 2013-04-24 Pharmahungary 2000 Kft. Compounds for treatment of ischemic injury
CN104619353A (zh) * 2011-12-13 2015-05-13 俄亥俄州国家创新基金会 与miR-21和miR-29a相关的方法和组合物、外切体抑制和癌症转移
CN102533979A (zh) * 2011-12-15 2012-07-04 苏州福英基因科技有限公司 各种癌症病理演变前期microrna-520水平原位杂交检测试剂盒及检测方法和应用
ES2432853B1 (es) 2011-12-15 2015-03-09 Fundación Para La Investigación Biomédica Del Hospital Universitario Ramón Y Cajal Metodo para el diagnostico y/o pronostico de dano renal agudo
JP2015511121A (ja) 2012-01-20 2015-04-16 ジ・オハイオ・ステート・ユニバーシティ 浸潤性および予後に関する乳がんバイオマーカーシグネチャー
CN103372218B (zh) * 2012-04-19 2016-05-04 中国科学院上海生命科学研究院 自身免疫性疾病相关的microRNA及其应用
WO2013165320A1 (en) * 2012-05-04 2013-11-07 Agency For Science, Technology And Research Treating cancer by increasing expression of socs6
CN102676522B (zh) * 2012-05-16 2013-04-10 北京旷博生物技术有限公司 乳腺癌分子标志物miR-195-5p
CN102676524B (zh) * 2012-05-16 2013-04-03 北京旷博生物技术有限公司 乳腺癌分子标志物miR-147a
WO2013192576A2 (en) 2012-06-21 2013-12-27 Miragen Therapeutics Oligonucleotide-based inhibitors comprising locked nucleic acid motif
CN102839173B (zh) * 2012-08-24 2013-09-04 中国医科大学附属第一医院 HIV感染疾病进展分子标志物miR-200c
CN102839172B (zh) * 2012-08-24 2013-09-25 中国医科大学附属第一医院 HIV感染疾病进展分子标志物miR-503
US10942184B2 (en) 2012-10-23 2021-03-09 Caris Science, Inc. Aptamers and uses thereof
BR112015009138A2 (pt) * 2012-10-23 2020-10-20 Caris Life Sciences Switzerland Holdings, S.A.R.L. métodos para caracterizar um câncer
WO2014075822A1 (en) 2012-11-16 2014-05-22 Siemens Aktiengesellschaft New diagnostic mirna markers for parkinson disease
EP2733219B1 (en) * 2012-11-16 2017-09-20 Siemens Aktiengesellschaft Diagnostic miRNA markers for Alzheimer
EP2733220B1 (en) 2012-11-16 2017-10-18 Siemens Aktiengesellschaft Novel miRNA as a diagnostic marker for Alzheimer's Disease
EP2746406B1 (en) * 2012-12-18 2017-08-23 Samsung Electronics Co., Ltd. Composition and kit for diagnosing breast cancer including miRNAs within vesicle, and method of diagnosing breast cancer using the same
JP6441567B2 (ja) * 2012-12-18 2018-12-19 三星電子株式会社Ｓａｍｓｕｎｇ Ｅｌｅｃｔｒｏｎｉｃｓ Ｃｏ．，Ｌｔｄ． 小胞内のポリヌクレオチドを含む乳がん診断用組成物及びキット、並びにそれを利用した乳がん診断方法
AU2013361323B2 (en) 2012-12-19 2018-09-06 Caris Science, Inc. Compositions and methods for aptamer screening
US9193970B1 (en) * 2013-03-14 2015-11-24 Raadysan Biotech, Inc. Replication factor C-40 (RFC40/RFC2) as a prognostic marker and target in estrogen positive and negative and triple negative breast cancer
US9970012B2 (en) 2013-03-14 2018-05-15 Raadysan Biotech, Inc. Replication factor C-40 (RFC40/RFC2) as a prognostic marker and target in estrogen positive and negative and triple negative breast cancer
US9546366B2 (en) 2013-03-14 2017-01-17 Raadysan Biotech, Inc. Replication factor C-40 (RFC40/RFC2) as a prognostic marker and target in estrogen positive and negative and triple negative breast cancer
MX2015013141A (es) * 2013-03-15 2016-06-21 Univ Texas Biogénesis de miarn en exosomas para diagnóstico y terapia.
JP6443889B2 (ja) * 2013-08-08 2018-12-26 国立大学法人大阪大学 尿路上皮癌の診断または治療剤
EP3071712B1 (en) 2013-11-18 2020-06-24 DiamiR, LLC Methods of using mirnas from bodily fluids for detection and monitoring of parkinson's disease (pd)
CN103602747B (zh) * 2013-11-28 2014-11-05 山东大学齐鲁医院 一种用于膀胱癌血清miRNA检测的内参及其检测引物与应用
US10815527B2 (en) * 2013-12-19 2020-10-27 Hummingbird Diagnostics Gmbh Determination of platelet-miRNAs in alzheimer's disease
US9758773B2 (en) 2014-02-14 2017-09-12 Agilent Technologies, Inc. Thermostable type-A DNA polymerase mutant with increased resistance to inhibitors in blood
JP6415829B2 (ja) * 2014-02-28 2018-10-31 キヤノンメディカルシステムズ株式会社 検体に含まれるエキソソームの特性を判定する方法、診断方法および装置
CN116004821A (zh) * 2014-08-15 2023-04-25 深圳市晋百慧生物有限公司 用于检测肠癌的标记物及其应用
CN107636003A (zh) 2015-01-20 2018-01-26 米拉根医疗股份有限公司 miR‑92抑制剂及其用途
EP3256602B1 (en) 2015-02-11 2019-09-04 QIAGEN GmbH A microrna-based method for early detection of prostate cancer in urine samples
JP6769979B2 (ja) 2015-02-27 2020-10-14 キアゲン ゲゼルシャフト ミット ベシュレンクテル ハフツング マイクロｒｎａに基づく前立腺がん患者の予後評価方法
ES2741591T3 (es) * 2015-03-13 2020-02-11 Univ Hiroshima Método para ayudar a la detección de la enfermedad de Alzheimer o una discapacidad cognitiva moderada
AU2016287499B2 (en) 2015-06-29 2022-08-04 Caris Science, Inc. Therapeutic oligonucleotides
US10941176B2 (en) 2015-07-28 2021-03-09 Caris Science, Inc. Therapeutic oligonucleotides
KR102601499B1 (ko) * 2015-11-06 2023-11-13 연세대학교 산학협력단 miRNA 발현 수준으로부터 UQCRB 관련 질병을 진단하는 방법
ITUB20155765A1 (it) 2015-11-20 2017-05-20 Braindtech S R L Metodi per diagnosi, prognosi e monitoraggio terapeutico di patologie neurologiche, neurodegenerative e infiammatorie basati su microRNA contenuto in microvescicole microglia
CN106729750A (zh) * 2015-11-20 2017-05-31 昆山彭济凯丰生物科技有限公司 通过miR-183治疗高血脂、脂肪肝、二型糖尿病和降低体重的方法和药物及它们的应用
CN105400785A (zh) * 2015-12-01 2016-03-16 中国人民解放军第四军医大学 一种与他莫昔芬耐药性相关的microRNA分子MiR-200a及其应用
CN105586401A (zh) * 2015-12-14 2016-05-18 常州杰傲医学检验所有限公司 一种用于乳腺癌诊断的miRNA标志物、其应用及诊断试剂盒
US10975436B2 (en) 2016-01-05 2021-04-13 Diamir, Llc Methods of using miRNA from bodily fluids for diagnosis and monitoring of neurodevelopmental disorders
CN105567826A (zh) * 2016-01-25 2016-05-11 苏州大学附属第二医院 has-miR-29b-3p的检测
WO2017161357A1 (en) 2016-03-18 2017-09-21 Caris Science, Inc. Oligonucleotide probes and uses thereof
CN105755123A (zh) * 2016-03-21 2016-07-13 河北医科大学第医院 一种结直肠癌相关的标志物、其引物及应用
US11149313B2 (en) 2016-03-21 2021-10-19 Diamir, Llc Methods of using miRNAs from bodily fluids for detection and differentiation of neurodegenerative diseases
CN105603113B (zh) * 2016-03-30 2019-02-05 江苏省疾病预防控制中心 HIV-1早期感染相关的血清miRNA在制备试剂盒中的应用
CA3025486A1 (en) 2016-05-25 2017-11-30 Caris Science, Inc. Oligonucleotide probes and uses thereof
CN106282360B (zh) * 2016-08-31 2019-11-08 武汉博杰生物医学科技有限公司 一种用于结肠癌预测转移的血浆miRNA组合、其探针组合物及应用
US11236337B2 (en) 2016-11-01 2022-02-01 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
AU2017353907B2 (en) 2016-11-01 2023-11-30 The Research Foundation For The State University Of New York 5-halouracil-modified microRNAs and their use in the treatment of cancer
CN108938659A (zh) * 2017-05-19 2018-12-07 昆山彭济凯丰生物科技有限公司 一种调节食欲和体重的方法和药物及它们的应用
WO2019008415A1 (en) * 2017-07-05 2019-01-10 Datar Rajan EXOSOMED AND PBMC GENE EXPRESSION ANALYSIS FOR CANCER CARE
US10781487B2 (en) 2017-07-24 2020-09-22 Diamir, Llc miRNA-based methods for detecting and monitoring aging
CN107557467B (zh) * 2017-08-10 2021-05-11 李永东 一种与脑动脉瘤相关的临床标志物及其应用
JP2019050772A (ja) * 2017-09-15 2019-04-04 国立大学法人 熊本大学 ワクチン接種後副反応を予測する検査方法
EP3724334A1 (en) * 2017-12-14 2020-10-21 Unicyte EV AG Pharmaceutical carriers containing mirnas for use in the treatment of renal cancer
WO2019144183A1 (en) * 2018-01-23 2019-08-01 La Trobe University Biomarkers of colorectal cancer
CN108295268A (zh) * 2018-02-05 2018-07-20 苏州吉玛基因股份有限公司 与肝癌诊疗相关的血清外泌体hsa-miR-93及其应用
CN111742060A (zh) 2018-02-13 2020-10-02 东丽株式会社 用于痴呆的检测的试剂盒或器件和方法
CN108103202A (zh) * 2018-03-06 2018-06-01 苏州吉玛基因股份有限公司 与肝癌诊疗相关的7种血清外泌体miRNAs及其应用
CN108546752B (zh) * 2018-04-20 2021-08-31 南京医科大学 检测和/或预测人类巨大儿的miRNA标志物或其组合及其应用
CN108676880B (zh) * 2018-05-24 2021-01-01 武汉大学 一种人血清afp阴性肝细胞癌检测试剂盒
CN109022587B (zh) * 2018-09-13 2022-02-22 南京求臻基因科技有限公司 一种急性髓系白血病的miRNA标志物及其应用
KR102256747B1 (ko) * 2018-10-30 2021-05-25 가톨릭대학교 산학협력단 엑소좀 miR-125b를 포함하는 간암 전이 진단 또는 예측용 바이오마커 및 이의 용도
KR102131519B1 (ko) * 2018-10-30 2020-07-07 가톨릭대학교 산학협력단 간암 전이 진단 또는 예후 예측용 바이오마커 및 이의 용도
CN109295213A (zh) * 2018-11-01 2019-02-01 中国人民解放军第00医院 免疫性血小板减少症的miRNA标志物及试剂盒和应用
CN109295001A (zh) * 2018-11-14 2019-02-01 姜大奎 一种脐带间充质干细胞复合外泌体及其制备方法
CN109971851A (zh) * 2019-01-22 2019-07-05 宁波大学 MiR-125b-2-3p作为鉴别诊断肾癌亚型的分子标志物及其在肿瘤转移中的用途
CN109777874B (zh) * 2019-01-29 2022-11-11 上海长海医院 一种适用于胰腺导管腺癌诊断及预后判断的血浆外泌体miRNA标志物及应用
CN109837343B (zh) * 2019-02-22 2024-03-01 中国科学院北京基因组研究所 早期肺腺癌特异性外泌体miRNA及其应用
US10900091B2 (en) * 2019-03-15 2021-01-26 The Chinese University Of Hong Kong miR-133a as a marker for colorectal cancer
CN110699450A (zh) * 2019-05-22 2020-01-17 璞晞（广州）生物免疫技术有限公司 miRNA生物标志物在肝脏疾病诊断和预后判断中的应用
CN110791560B (zh) * 2019-11-06 2021-09-14 中国医学科学院医药生物技术研究所 一种用于阿尔茨海默病诊断和/或治疗的miRNA标志物
ES2856232B2 (es) * 2020-03-25 2023-11-24 Fundacion Para La Investig Biomedica Del Hospital 12 De Octubre Biomarcadores para predecir la respuesta de un sujeto a una terapia con bcg, metodos y usos basados en los mismos
US20230407401A1 (en) * 2020-05-29 2023-12-21 National Institute Of Immunology Dna damage dependent microrna signature for cancers, methods and uses related thereto
CN112494654B (zh) * 2020-12-10 2021-12-17 暨南大学附属第一医院（广州华侨医院） 包含LncRNA HCG18抑制剂的药物组合物及其应用
CN114469996B (zh) * 2021-12-23 2023-10-20 中国医学科学院医学生物学研究所 一种包含miR-135b-5p的外泌体及在抗轮状病毒感染中的应用
CN115192710A (zh) * 2022-05-27 2022-10-18 华南理工大学 一种miRNA-200s保护剂在制备神经系统疾病类药物中的应用和药物及模型构建方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5089181A (en) 1987-02-24 1992-02-18 Vestar, Inc. Method of dehydrating vesicle preparations for long term storage
US6812023B1 (en) 2000-04-27 2004-11-02 Anosys, Inc. Methods of producing membrane vesicles
US20050159378A1 (en) * 2001-05-18 2005-07-21 Sirna Therapeutics, Inc. RNA interference mediated inhibition of Myc and/or Myb gene expression using short interfering nucleic acid (siNA)
US20030036077A1 (en) 2001-05-31 2003-02-20 Chronix Biomedical Methods for generating an mRNA expression profile from an ecellular mRNA containing blood sample and using the same to identify functional state markers
US20050158708A1 (en) 2001-06-06 2005-07-21 Iris Alroy Methods and compositions related to tagging of membrane surface proteins
US20070077553A1 (en) * 2003-10-30 2007-04-05 Rosetta Genomics Bioinformatically detectable group of novel vaccinia regulatory genes and uses thereof
US20050064470A1 (en) * 2003-07-17 2005-03-24 Rana Tariq M. High throughput screening methods for identifying RNA binding compounds
US8293522B2 (en) 2004-05-13 2012-10-23 Centre National De La Recherche Scientifique Device for binding a target entity to a bait entity and detection methods using the same
EP2290071B1 (en) 2004-05-28 2014-12-31 Asuragen, Inc. Methods and compositions involving microRNA
EP1766053A4 (en) * 2004-06-02 2007-12-12 Sourcepharm Inc MICROVESICLES CONTAINING RNA AND METHODS
US8021847B2 (en) 2004-06-02 2011-09-20 Proxy Life Science Holdings, Inc. Microvesicle-based compositions and methods
US9164108B2 (en) 2005-03-22 2015-10-20 Sri International Liposome-based microarray and methods of use thereof
ES2461189T3 (es) * 2006-01-05 2014-05-19 The Ohio State University Research Foundation Métodos basados en microARN y composiciones para el diagnóstico y el tratamiento de cánceres sólidos de mama o pulmón
WO2007084962A2 (en) 2006-01-18 2007-07-26 The Regents Of The University Of California A fluid membrane-based ligand display system for live cell assays and disease diagnosis applications
EP2806273B1 (en) * 2007-07-25 2017-09-06 University of Louisville Research Foundation, Inc. Exosome-associated microRNA as a diagnostic marker
ES2575868T3 (es) 2007-09-14 2016-07-01 The Ohio State University Research Foundation Expresión de miARN en microvesículas de sangre periférica humana y sus usos
EP2350320A4 (en) 2008-11-12 2012-11-14 Caris Life Sciences Luxembourg Holdings METHODS AND SYSTEMS FOR USING EXOSOMES TO DETERMINE PHENOTYPES

Also Published As

Publication number Publication date
WO2009036236A1 (en) 2009-03-19
EP3112464A1 (en) 2017-01-04
AU2008298744A8 (en) 2015-01-15
JP5624470B2 (ja) 2014-11-12
EP2610342A1 (en) 2013-07-03
ES2419129T3 (es) 2013-08-19
EP2190992A1 (en) 2010-06-02
CA2699646A1 (en) 2009-03-19
CN101842484A (zh) 2010-09-22
CN101842484B (zh) 2015-07-29
JP2010538653A (ja) 2010-12-16
EP2190992B1 (en) 2013-04-03
ES2575868T3 (es) 2016-07-01
IL204484A (en) 2015-02-26
EP2610342B1 (en) 2016-05-04
AU2008298744A1 (en) 2009-03-19
IL236831A0 (en) 2015-03-31
US20100279292A1 (en) 2010-11-04
US20130316925A1 (en) 2013-11-28
US20170009306A1 (en) 2017-01-12
EP2190992A4 (en) 2011-02-23
US10030273B2 (en) 2018-07-24
AU2008298744B8 (en) 2015-01-15
US8455199B2 (en) 2013-06-04
AU2008298744B2 (en) 2014-09-04
CN104975089A (zh) 2015-10-14

Similar Documents

Publication Publication Date Title
BRPI0816852A2 (pt) método de diagnosticar ou prognosticar doença ou desordem em sujeito, biomarcador, método para determinar e/ou prever se sujeito tem diferenciação da desordem, biomarcador para desordem pulmonar, método para diagnosticar se sujeito tem, ou está em risco de desenvolver doença ou desordem, método de inibir a proliferação de doença ou desordem e método para identificar agente terapêutico do câncer.
Li et al. Particulate matter‐induced epigenetic changes and lung cancer
Nosho et al. SIRT1 histone deacetylase expression is associated with microsatellite instability and CpG island methylator phenotype in colorectal cancer
BR112013006683A2 (pt) diagnóstico de câncer de mama
BR112015023783A2 (pt) método para diagnóstico e tratamento de metastase no câncer
BRPI1007321A2 (pt) métodos para medir e/ou quantificar a presença e/ou quantidade de her-3 ou her-3 em um complexo em uma amostra de um paciente, e para determinar se um indivíduo com um câncer é provável de responder ao tratamento com uma terapia alvejada, e, anticorpo.
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
WO2010018601A3 (en) Genetic variants predictive of cancer risk
WO2012166899A3 (en) Biomarkers for predicting and assessing responsiveness to lenvatinib compounds
WO2009015050A3 (en) Gene expression profile for predicting ovarian cancer patient survival
BRPI1007048A2 (pt) método e kit para correlacionar os níveis relativos da quantidade de pelo menos um de her-2 ou homodímeros de her-2 em uma amostra biológica de um indivíduo, e , método para prognosticar se um indivíduo com câncer e que é tratado com um agente que atua em her-2 é provável ter um evento significante.
Kaltenmeier et al. Neutrophil extracellular traps as a novel biomarker to predict recurrence-free and overall survival in patients with primary hepatic malignancies
BRPI0915240A2 (pt) método para tratar câncer, método para avaliação de um paciente submetido ao tratamento de câncer, método para avaliação de um paciente que tem ou com suspeita de ter câncer e uso de um anticorpo anti-c-met
BRPI0908065A2 (pt) Métodos para tratar um paciente que possui um ifn do tipo i ou doença ou distúrbio mediado por ifnalfa, para neutralizar um perfil de marcador mirna diferencialmente regulado em um paciente, para monitorar ou prognosticar uma progressão da doença inflamatória e da doença miosite de um paciente, para monitorar a progressão da doença inflamatória ou autoimune e da doença miosite de um paciente e para tratar um paciente com miosite
Dooley et al. Dosing of cytotoxic chemotherapy: impact of renal function estimates on dose
WO2007067476A3 (en) Methods for predicting treatment response based on the expression profiles of protein and transcription biomakers
BRPI0907637A8 (pt) biomarcadores p53
MX368099B (es) Biomarcadores para predecir y evaluar el grado de respuesta de sujetos con cancer de endometrio a compuestos de tipo lenvatinib.
Lotan et al. Screening for bladder cancer: a perspective
BR112014031414A2 (pt) métodos de detectar doenças ou condições utilizando células doentes circulantes
WO2008073177A3 (en) Expression profiles associated with irinotecan treatment
Devarajan The promise of biomarkers for personalized renal cancer care
WO2007124309A3 (en) Methods for detecting mutations in jak2 nucleic acid
Barnes et al. Chronic lung diseases: prospects for regeneration and repair
BR112013013457A2 (pt) métodos para identificar um paciente ou sujeito, para prever a sensibilidade de um sujeito, para identificar sujeitos que têm doença de parkinson e para determinar a resposta do sujeito à terapia e ensaio para seleção de compostos e composições

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B11E Dismissal acc. art. 34 of ipl - requirements for examination incomplete
B11T Dismissal of application maintained [chapter 11.20 patent gazette]